Emergent BioSolutions Inc.
Emergent BioSolutions Inc. (NYSE: EBS) is trading at $6.79, about ₹651 at today's USD/INR rate, as of 25 Sep 2026, 4:00 PM ET, up 0.30% today. Indian residents can buy Emergent BioSolutions from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$6.67
Today's high
$6.85
52 week low
$4.36
52 week high
$14.06
EBS opened at $6.76, closed previously at $6.77, and has traded between $4.36 and $14.06 over the past 52 weeks.
About
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
Key statistics
Avg. volume
1.07M
Market cap
$350.34M
P/E Ratio
-1.97
Price-to-sales ratio
0.45
Enterprise value
$792.44M
Free cash flow yield
24.52%
Debt-to-equity ratio
1.70
Return on equity
-35.91%
ROIC
-5.47%
Beta
2.34
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
$742.90M
Earnings per share
$0.98
Free cash flow
$156.80M
Net profit margin
-22.96%
Gross margin
49.40%
EBITDA
$240.40M
Revenue growth
-28.81%
Similar securities
This is not an investment recommendation
How to buy Emergent BioSolutions from India
Indian residents can buy Emergent BioSolutions shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for Emergent BioSolutions and place an order
Find Emergent BioSolutions by name or by its ticker, EBS, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Emergent BioSolutions trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Emergent BioSolutions position in USD and INR. Emergent BioSolutions pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Emergent BioSolutions from India
Trading and taxes when buying Emergent BioSolutions from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneEmergent BioSolutions does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- US estate tax
- May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy Emergent BioSolutions stock?
Yes. Emergent BioSolutions (EBS) has been listed on the New York Stock Exchange since 2006, in the Drug Manufacturers - Specialty & Generic industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one Emergent BioSolutions share cost in rupees?
One Emergent BioSolutions share is $6.79 — about ₹651 at a USD/INR rate of 95.92 on 25 Sep 2026. Both the Emergent BioSolutions price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Emergent BioSolutions from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy whole shares of Emergent BioSolutions?
Yes. One Emergent BioSolutions share is $6.79, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in Emergent BioSolutions.
How are gains on Emergent BioSolutions shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Emergent BioSolutions price. Paasa issues a capital-gains statement for your return.
Does Emergent BioSolutions pay a dividend?
No. Emergent BioSolutions does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Emergent BioSolutions from India?
The New York Stock Exchange trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is there estate or inheritance tax on Emergent BioSolutions shares held from India?
US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.
Do I have to declare Emergent BioSolutions shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Emergent BioSolutions holding, its cost and its closing value.
How do I sell Emergent BioSolutions and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.